Niraparib

Small molecule

Also known as GSK3985771

Approvedregulatory verdict

Evidence outlook

Approved: Ovarian Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Non-Small Cell Lung Cancer · Phase 3Glioblastoma · Phase 3

Also approved (4)
US
  • Maintenance Treatment of Recurrent Germline BRCA -Mutated Ovarian Cancer ZEJULA is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g BRCA mut) recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA‑authorized companion diagnostic for ZEJULA [see Dosage and Administration ( 2.1 )] .
Product first approved 2023FDA label
CN
  • Maintenance therapy, recurrent ovarian cancer (brand Zejula, Zai Lab)
Product first approved 2019americanpharmaceuticalreview.com
CA
  • ZEJULA (niraparib capsules and tablets) is indicated: • as monotherapy for the maintenance treatment of female adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. • as monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Product first approved 2019Health Canada
EU
  • Zejula is indicated: as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.
Product first approved 2017EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (21)
Glioblastoma
NCT06388733 · Ivy Brain Tumor Center
2024-06-19 – 2028-03 · Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor
What this study did
Non-Small Cell Lung Cancer
Ovarian Cancer
NCT05659381 · GOG Foundation
2024-03-08 – 2034-08-01 · Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer
What this study did
NCT06915025 · Imunon
2025-07-09 – 2032-10-31 · Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
What this study did
NCT05009082 · AGO Study Group
2022-09-13 – 2031-12 · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
What this study did
NCT03602859 · Tesaro, Inc.
2018-10-11 – 2029-04-30 · Ovarian Neoplasms, Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
What this study did
NCT04679064 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2020-12-01 – 2025-01-01 · Ovarian Cancer
What this study did
NCT03806049 · Nordic Society of Gynaecological Oncology - Clinical Trials Unit
2019-12 – 2024-12 · Ovarian Cancer
What this study did
NCT03705156 · Zai Lab (Shanghai) Co., Ltd.
2017-06-08 – 2024-08-24 · Platinum-sensitive Relapsed Ovarian Cancer
What this study did
NCT03709316 · Zai Lab (Shanghai) Co., Ltd.
2018-06-30 – 2023-12-30 · Ovarian Cancer
What this study did
Other / comorbidity
NCT03768063 · Hoffmann-La Roche
2019-02-28 – 2028-07-05 · Cancer
What this study did
NCT05615818 · UNICANCER
2024-07-18 – 2028-06 · Biliary Tract Neoplasms
What this study did
NCT03748641 · Janssen Research & Development, LLC
2019-01-25 – 2027-12-31 · Castration-Resistant Prostatic Cancer
What this study did
NCT03903835 · Karolinska Institutet
2019-02-01 – 2026-12 · Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
What this study did
NCT01905592 · Tesaro, Inc.
2014-02-25 – 2021-10-26 · Neoplasms, Breast, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Neoplasms
What this study did
NCT03516084 · Zai Lab (Shanghai) Co., Ltd.
2018-08-20 – 2020-03-20 · Extensive-stage Small Cell Lung Cancer
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT03651206 · ARCAGY/ GINECO GROUP
2020-07-15 – 2029-03 · Ovarian Carcinosarcoma, Endometrial Carcinosarcoma
What this study did
NCT04159155 · University Health Network, Toronto
2020-11-17 – 2025-05-26 · Endometrial Carcinoma, P53 Mutation, Serous Carcinoma
What this study did
Phase 2 (100)
Glioblastoma
NCT05297864 · University of Oklahoma
2022-06-09 – 2024-02-06 · Recurrent Glioblastoma, Recurrent Astrocytoma, Recurrent Oligodendroglioma, Recurrent Glioma
What this study did
NCT04715620 · Tianjin Huanhu Hospital
2021-01 – 2023-01 · Recurrent Glioblastoma
What this study did
Non-Small Cell Lung Cancer
NCT04940637 · University of Turin, Italy
2020-12-23 – 2025-06-30 · Lung Cancer, Mesothelioma
What this study did
NCT03308942 · Tesaro, Inc.
2017-09-29 – 2021-08-31 · Neoplasms
What this study did
Ovarian Cancer
NCT05460000 · North Eastern German Society of Gynaecological Oncology
2024-10-11 – 2032-10-01 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma
What this study did
NCT05183984 · ARCAGY/ GINECO GROUP
2022-02-01 – 2032-02-01 · Ovarian Cancer
What this study did
NCT06141265 · Peking University Cancer Hospital & Institute
2023-11-01 – 2028-12 · Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
What this study did
NCT06180356 · MedSIR
2024-12-03 – 2028-01 · Ovarian Cancer, Oligometastatic Disease, Serous Ovarian Tumor
What this study did
NCT05990192 · Institute of Cancer Research, United Kingdom
2024-06-20 – 2027-12-31 · Ovarian Cancer Recurrent
What this study did
NCT05335993 · CanariaBio Inc.
2022-07-25 – 2027-12-30 · Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Peritoneal Cancer, Recurrent Carcinoma of Ovary, Adenocarcinoma of Ovary
What this study did
NCT05961124 · Sunnybrook Health Sciences Centre
2023-08-21 – 2027-09 · Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, High Grade Ovarian Serous Adenocarcinoma
What this study did
NCT04734665 · Yonsei University
2021-07-05 – 2027-05-31 · Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
What this study did
NCT04507841 · Tongji Hospital
2021-01-08 – 2026-12-31 · Ovarian Cancer
What this study did
NCT05126342 · AGO Research GmbH
2023-11-01 – 2026-11-01 · Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did
NCT06433219 · EMD Serono Research & Development Institute, Inc.
2024-10-30 – 2026-08-11 · Ovarian Cancer
What this study did
NCT05065021 · University Health Network, Toronto
2023-02-23 – 2025-06-06 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High Grade Serous Cancer, High Grade Endometrioid Cancer
What this study did
NCT05641506 · Sichuan Cancer Hospital and Research Institute
2022-12 – 2025-05 · Ovarian Cancer
What this study did
NCT03574779 · Tesaro, Inc.
2018-11-15 – 2025-03-31 · Ovarian Neoplasms
What this study did
NCT05385068 · Peking Union Medical College Hospital
2022-06 – 2024-09 · Epithelial Ovarian Cancer
What this study did
NCT03891576 · Mario Negri Institute for Pharmacological Research
2019-11-13 – 2024-08-31 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
What this study did
NCT05311579 · Lei Li
2022-03-27 – 2024-03-27 · Ovarian Carcinoma, Survival Outcomes, Adverse Events, Niraparib, Anlotinib, CA125, Chemotherapy, Targeted Therapy, Recurrent Ovarian Cancer
What this study did
NCT04284852 · The University of Hong Kong
2020-05-01 – 2023-10-01 · Ovarian Cancer
What this study did
NCT03783949 · Universitaire Ziekenhuizen KU Leuven
2018-11-30 – 2023-09-01 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
What this study did
NCT05130515 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2021-12-15 – 2023-01-01 · Platinum-resistant Recurrent Clear Cell Ovarian Cancer
What this study did
NCT03759587 · Takeda
2018-12-28 – 2022-12-28 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did
NCT03759600 · Takeda
2018-12-26 – 2022-12-28 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
What this study did
NCT04556071 · Xiaoxiang Chen
2020-11-06 – 2022-10-01 · Ovarian Neoplasms, Fallopian Tube Neoplasms, Endocrine Gland Neoplasms, Neoplasms by Site, Neoplasms, Genital Neoplasms, Female, Urogenital Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Carcinoma, Ovarian Epithelial, Ovarian Diseases, Adnexal Diseases, Genital Diseases, Female, Endocrine System Diseases, Gonadal Disorders, Carcinoma, Bevacizumab, Enzyme Inhibitors, Antineoplastic Agents, Molecular Mechanisms of Pharmacological Action, Angiogenesis, BRCA1 Mutation, BRCA2 Mutation, Homologous Recombination Deficiency
What this study did
NCT04392102 · Zai Lab (Shanghai) Co., Ltd.
2020-08-04 – 2022-08-11 · Ovarian Cancer
What this study did
NCT04217798 · Peking Union Medical College Hospital
2020-05-21 – 2022-06-01 · Ovarian Cancer
What this study did
NCT05751629 · Tesaro, Inc.
2018-11-15 – 2022-04-01 · Ovarian Neoplasm
What this study did
NCT04376073 · Jihong Liu
2020-05-22 – 2022-03-31 · Platinum-resistant Ovarian Cancer
What this study did
NCT02354586 · Tesaro, Inc.
2015-03-23 – 2021-08-23 · Ovarian Neoplasms, Ovarian Cancer
What this study did
Other / comorbidity
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT05232006 · Assistance Publique - Hôpitaux de Paris
2022-05 – 2030-05 · Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
What this study did
NCT04341181 · Ulrik Lassen
2020-08-24 – 2030-04-30 · Cancer, Tumors, Neoplasms, Neoplasia
What this study did
NCT05700721 · M.D. Anderson Cancer Center
2023-06-02 – 2029-12-31 · Brain Metastases
What this study did
NCT06212583 · University of Maryland, Baltimore
2024-04-17 – 2029-12-31 · Prostate Cancer, Oligometastatic Disease
What this study did
NCT04837209 · Massachusetts General Hospital
2021-07-21 – 2029-12-01 · Breast Cancer, Triple Negative Breast Cancer
What this study did
NCT04584255 · Dana-Farber Cancer Institute
2021-01-21 – 2029-07-17 · Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
What this study did
NCT06392841 · Qian Qin
2025-10 – 2029-01-31 · Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CHEK2 Gene Mutation, FANCA Gene Mutation, PALB2 Gene Mutation, RAD51B Gene Mutation, RAD54L Gene Mutation
What this study did
NCT06747845 · Abramson Cancer Center at Penn Medicine
2025-05-07 – 2029-01-30 · Pancreatic Adenocarcinoma Metastatic
What this study did
NCT04423185 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2020-08-15 – 2028-07-01 · Rare Tumor
What this study did
NCT05601440 · Canadian Cancer Trials Group
2023-06-13 – 2028-06-30 · Breast Cancer
What this study did
NCT04947254 · M.D. Anderson Cancer Center
2021-08-05 – 2028-06-07 · Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
What this study did
NCT04681469 · Gruppo Oncologico del Nord-Ovest
2021-02-08 – 2028-06 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06527690 · Latin American Cooperative Oncology Group
2025-04-30 – 2028-02-28 · Prostate Cancer, Castrate Resistant Prostate Cancer, Homologous Recombination Deficiency
What this study did
NCT06365970 · Ibrahim Halil Sahin
2025-01-31 – 2028-01 · MMR-D/MSI-H Colorectal Cancers
What this study did
Phase 1/2 (23)
Glioblastoma
NCT06258018 · Armando Santoro, MD
2024-09 – 2027-09 · Glioma, Malignant
What this study did
Ovarian Cancer
NCT06594679 · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
2024-09-26 – 2027-09-18 · Ovarian Cancer
What this study did
NCT05672095 · City of Hope Medical Center
2025-04-18 – 2026-11-27 · Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
What this study did
NCT05198804 · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
2022-01-27 – 2026-01-19 · Ovarian Cancer, Platinum-resistant Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
What this study did
NCT02354131 · Nordic Society of Gynaecological Oncology - Clinical Trials Unit
2015-02-15 – 2021-12-15 · Ovarian Cancer
What this study did
NCT02657889 · Tesaro, Inc.
2016-04-15 – 2021-09-17 · Neoplasms, Triple Negative Breast Cancer, Ovarian Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Stage IV Breast Cancer, Fallopian Tube Cancer, Peritoneal Cancer
What this study did
Other / comorbidity
NCT06953323 · Wigen Biomedicine Technology (Shanghai) Co., Ltd.
2025-07-10 – 2029-12-30 · Advanced Solid Tumor
What this study did
NCT06682780 · LaNova Medicines Limited
2025-09-17 – 2029-12-01 · Advanced Solid Tumor
What this study did
NCT04194554 · University of Michigan Rogel Cancer Center
2020-11-06 – 2029-05 · Prostate Cancer
What this study did
NCT05784012 · Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
2023-11-13 – 2029-03 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT06329830 · Baptist Health South Florida
2024-10 – 2028-10 · Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
What this study did
NCT03368729 · University of Alabama at Birmingham
2019-09-06 – 2027-12-30 · Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
What this study did
NCT05519670 · Institut Paoli-Calmettes
2023-03 – 2027-12 · Breast Cancer
What this study did
NCT03830918 · Jonsson Comprehensive Cancer Center
2019-03-06 – 2027-01-03 · Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT04037254 · NRG Oncology
2019-10-08 – 2025-12-23 · Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
What this study did
NCT03869190 · Hoffmann-La Roche
2019-06-01 – 2025-12-22 · Urothelial Carcinoma, Bladder Cancer
What this study did
NCT04972110 · Repare Therapeutics
2021-07-21 – 2024-11-13 · Advanced Solid Tumor, Adult
What this study did
NCT03404960 · University of Pennsylvania
2018-01-31 – 2024-10-09 · Pancreatic Adenocarcinoma
What this study did
NCT03425201 · Fundacion CRIS de Investigación para Vencer el Cáncer
2019-10-14 – 2024-07-31 · Urothelial Cancer
What this study did
NCT03644342 · Michelle S Ludwig
2019-07-15 – 2023-09-27 · Metastatic Carcinoma of the Cervix
What this study did
NCT04655183 · EMD Serono Research & Development Institute, Inc.
2020-12-01 – 2023-09-01 · Advanced Solid Tumor, Breast Cancer
What this study did
NCT03221400 · Tarveda Therapeutics
2017-08-29 – 2023-06 · Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
What this study did
Phase 1 (46)
Glioblastoma
NCT05076513 · Nader Sanai
2021-10-29 – 2027-03 · Glioblastoma, Glioblastoma Multiforme, Glioma, GBM, Glioma, Malignant, Glioblastoma Multiforme of Brain
What this study did
NCT05666349 · University College, London
2023-10-13 – 2023-10-13 · Recurrent Glioblastoma
What this study did
NCT01294735 · Merck Sharp & Dohme LLC
2011-02 – 2012-05 · Recurrence of Solid Tumor, Glioblastoma Multiforme, Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT03307785 · Tesaro, Inc.
2017-10-12 – 2024-12-11 · Neoplasms, Metastatic Cancer, Advanced Cancer, Solid Tumor, Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage IIIB, Non Small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT06161493 · Haider Mahdi
2024-01-23 – 2029-12-31 · Ovarian Cancer, Recurrent Solid Tumors
What this study did
NCT04502602 · Virginia Commonwealth University
2020-08-24 – 2027-10-31 · Advanced Solid Tumor, Ovarian Cancer
What this study did
NCT04673448 · University of Washington
2021-10-18 – 2027-09-30 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, BRCA-Associated Malignant Neoplasm, BRCA Hereditary Ovarian Carcinoma, Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Primary Peritoneal Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Unresectable Breast Carcinoma, Unresectable Fallopian Tube Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Ovarian Carcinoma, Unresectable Pancreatic Carcinoma, Unresectable Primary Peritoneal Carcinoma
What this study did
NCT04149145 · University of Alabama at Birmingham
2023-05 – 2027-05 · Ovarian Cancer Recurrent
What this study did
NCT05238831 · OHSU Knight Cancer Institute
2023-01-30 – 2026-05-31 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT04267939 · Bayer
2020-02-26 – 2023-12-01 · Advanced Solid Tumors (Excluding Prostate Cancer), Ovarian Cancer
What this study did
NCT03154281 · Avera McKennan Hospital & University Health Center
2017-07-26 – 2023-05-01 · Breast Cancer, Ovarian Cancer
What this study did
NCT03944902 · University of Alabama at Birmingham
2021-09-01 – 2022-01-05 · Ovarian Cancer, Resistant BRCA Wild-Type Ovarian Cancer
What this study did
NCT03895788 · Hunan Cancer Hospital
2019-01-14 – 2020-03 · Ovarian Cancer
What this study did
NCT03551171 · Zai Lab (Shanghai) Co., Ltd.
2017-12-19 – 2018-07-10 · Ovarian Cancer
What this study did
NCT01227941 · Tesaro, Inc.
2010-11 – 2011-09 · Ovarian Cancer
What this study did
Other / comorbidity
NCT03945721 · Massachusetts General Hospital
2019-07-11 – 2028-12-31 · Triple Negative Breast Cancer, Residual Disease
What this study did
NCT05694715 · University of California, San Francisco
2023-05-23 – 2028-08-31 · Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, PALB2 Gene Mutation
What this study did
NCT04577833 · Janssen Research & Development, LLC
2020-11-13 – 2027-12-31 · Prostatic Neoplasms
What this study did
NCT04170153 · EMD Serono Research & Development Institute, Inc.
2019-12-20 – 2026-10-14 · Metastatic or Locally Advanced Unresectable Solid Tumors
What this study did
NCT05406700 · Massachusetts General Hospital
2023-05-18 – 2026-10 · Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma, IDH1 Mutation, Glioma, Malignant
What this study did
NCT03586661 · M.D. Anderson Cancer Center
2019-04-29 – 2026-06-16 · Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Progressive Disease, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
What this study did
NCT05289648 · Sir Mortimer B. Davis - Jewish General Hospital
2024-05-01 – 2026-01-31 · Endometrial Cancer, Serous Adenocarcinoma, Uterine Neoplasm
What this study did
NCT04762901 · Wake Forest University Health Sciences
2021-04-01 – 2026-01 · Breast Cancer
What this study did
NCT04991480 · Artios Pharma Ltd
2021-09-13 – 2025-12-24 · Advanced Cancer, Metastatic Cancer, Breast Cancer
What this study did
NCT04926324 · University of Iowa
2022-07-07 – 2025-11-24 · Rectal Neoplasms, Rectal Neoplasm Malignant
What this study did
NCT04481113 · OHSU Knight Cancer Institute
2021-06-07 – 2025-06-20 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, HER2 Negative Breast Adenocarcinoma, Hormone Receptor Positive Breast Adenocarcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Unilateral Breast Carcinoma
What this study did
NCT04544995 · GlaxoSmithKline
2020-10-06 – 2025-04-23 · Neoplasms
What this study did
NCT03891615 · Massachusetts General Hospital
2019-06-06 – 2024-11-07 · Lung Cancer
What this study did
NCT03209401 · Georgetown University
2017-10-13 – 2023-10-16 · Solid Tumor, Adult, Homologous Recombination Deficiency
What this study did
NCT05261269 · Dantari, Inc.
2022-02-02 – 2023-10-11 · HER2-negative Metastatic Breast Cancer
What this study did
NCT03329001 · Tesaro, Inc.
2017-12-04 – 2023-06-15 · Neoplasms
What this study did
NCT04235101 · Byondis B.V.
2020-06-22 – 2023-04-24 · Solid Tumor
What this study did
NCT04764084 · Peking University Cancer Hospital & Institute
2021-04-01 – 2023-02-28 · HER2-negative Breast Cancer, Gastric Adenocarcinoma, Cholangiocarcinoma, Pancreatic Cancer
What this study did
NCT03076203 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2017-09-22 – 2022-11-07 · Prostate Carcinoma Metastatic to the Bone, Stage IV Prostate Adenocarcinoma, Hormone-refractory Prostate Cancer
What this study did
NCT04178460 · Zai Lab (Shanghai) Co., Ltd.
2020-02-03 – 2022-03-02 · Gastric Cancer, Triple Negative Breast Cancer, Biliary Tract Carcinoma, Endometrial Carcinoma
What this study did
NCT02044120 · Sarcoma Alliance for Research through Collaboration
2014-05 – 2021-01 · Ewing Sarcoma
What this study did
NCT03359850 · Tesaro, Inc.
2018-02-20 – 2020-06-24 · Ovarian Neoplasms, Neoplasms, Solid Tumor, Hepatic Impairment
What this study did
NCT03329937 · Tesaro, Inc.
2018-04-12 – 2020-03-31 · Neoplasms, Breast
What this study did
NCT03497429 · Takeda
2018-04-05 – 2020-02-10 · Advanced Solid Tumors
What this study did
NCT02924766 · Janssen Research & Development, LLC
2016-10-03 – 2019-07-19 · Prostatic Neoplasms
What this study did
NCT02476552 · Tesaro, Inc.
2015-02 – 2018-01 · Cancer
What this study did
NCT02500901 · Paul Mathew, MD
2016-03 – 2016-05-10 · Metastatic Prostate Cancer
What this study did
NCT00749502 · Tesaro, Inc.
2008-09 – 2013-06 · Solid Tumors, Chronic Lymphocytic Leukemia, T-cell-prolymphocytic Leukemia
What this study did
NCT01226901 · Merck Sharp & Dohme LLC
2010-11 – 2011-11 · Neoplasms, Solid Tumors
What this study did
NCT01110603 · Tesaro, Inc.
2010-07 – 2011-07 · Cancer: Solid Tumors
What this study did
Phase 4 (5)
Ovarian Cancer
NCT06412120 · University of Miami
2026-07-28 – 2031-07-28 · Ovarian Cancer
What this study did
NCT06887933 · GlaxoSmithKline
2025-04-22 – 2026-07-08 · Ovarian Neoplasms
What this study did
NCT05187208 · Seoul National University Hospital
2022-01 – 2025-12 · Epithelial Ovarian Cancer, Ovarian Cancer, Ovarian Cancer Stage III, Ovarian Cancer Stage IV
What this study did
NCT04861181 · Hospices Civils de Lyon
2021-05-05 – 2025-04-17 · Adult Patients With Platinum-sensitive, Relapsed, High Grade Serous Epithelial Ovarian Cancer
What this study did
NCT03752216 · ARCAGY/ GINECO GROUP
2019-04-03 – 2022-12-13 · Ovarian Cancer
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT04589039 · Takeda
2020-03-16 – 2024-09-11 · Ovarian Neoplasms
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1/2 (1)
Other / comorbidity
Appears in other studies (4)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Ovarian Cancer
NCT03598270 · Grupo Español de Investigación en Cáncer de Ovario
2018-11-21 – 2024-08-05 · Recurrent Ovarian Carcinoma
What this study did
Phase 2 (3)
Glioblastoma
Niraparib/TTFields in GBMactive not recruiting
NCT04221503 · Abramson Cancer Center at Penn Medicine
2019-12-30 – 2026-01 · Glioblastoma, Recurrent Glioblastoma, GBM
What this study did
Ovarian Cancer
NCT03983226 · Shanghai Gynecologic Oncology Group
2019-10-18 – 2026-12 · Ovarian Cancer Recurrent, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
What this study did
NCT05523440 · University of Oklahoma
2023-02-15 – 2025-01-08 · Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, ARID1A Gene Mutation
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Glioblastoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Niraparib: this drugPhase 3Small moleculePARP1/2not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
TemozolomideApprovedSmall moleculeDNA alkylation (O6-guanine)not yet gradedNo reviewed efficacy summary in this indication
TemferonPhase 1/2Gene therapy / editingInterferon-alpha2 (myeloid-specific expression), Interferon-alpha2 (IFN-alpha2) expression in myeloid cellsnot yet gradedNo reviewed efficacy summary in this indication
TNG456Phase 1/2Small moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication
ZedoresertibPhase 1/2Small moleculeWEE1 kinasenot yet gradedNo reviewed efficacy summary in this indication
AZD1390Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
RalometostatDiscontinuedSmall moleculePRMT5not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(44 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Niraparib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (9)
November 2026 (2)
Phase 2Penile CarcinomaRecruiting
Est. primary completion 2026-11 · NCT05526989 · CT.gov ↗
What to watch
Phase 3NeoplasmsActive not recruiting
Est. primary completion 2026-11-26 · NCT03981796 · CT.gov ↗
What to watch
December 2026 (7)
Phase 1/2GlioblastomaNot yet recruiting
Est. primary completion 2026-12 · NCT06258018 · CT.gov ↗
What to watch
Phase 2SCLC,Extensive Stage, SLFN11-positiveRecruiting
Est. primary completion 2026-12 · NCT05718323 · CT.gov ↗
What to watch
Phase 3Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)Recruiting
Est. primary completion 2026-12 · NCT03903835 · CT.gov ↗
What to watch
Phase 2Metastatic Cancer, Central Nervous System CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04992013 · CT.gov ↗
What to watch
Phase 2Ovarian Neoplasms, Breast NeoplasmsRecruiting
Est. primary completion 2026-12-28 · NCT04641247 · CT.gov ↗
What to watch
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT05335993 · CT.gov ↗
What to watch
Phase 1Triple Negative Breast Cancer, Residual DiseaseActive not recruiting
Est. primary completion 2026-12-31 · NCT03945721 · CT.gov ↗
What to watch
2027 (19)
January 2027 (1)
Phase 1/2Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-01-03 · NCT03830918 · CT.gov ↗
What to watch
February 2027 (2)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-02 · NCT05183984 · CT.gov ↗
What to watch
Phase 2Breast Cancer, Triple Negative Breast CancerActive not recruiting
Est. primary completion 2027-02-01 · NCT04837209 · CT.gov ↗
What to watch
March 2027 (3)
Phase 1/2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-03 · NCT05784012 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-03 · NCT06141265 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerRecruiting
Est. primary completion 2027-03-20 · NCT06594679 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-04-30 · NCT04701307 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1/2Prostate CancerActive not recruiting
Est. primary completion 2027-05 · NCT04194554 · CT.gov ↗
What to watch
June 2027 (3)
Phase 2/3Ovarian Carcinosarcoma, Endometrial CarcinosarcomaRecruiting
Est. primary completion 2027-06 · NCT03651206 · CT.gov ↗
What to watch
Phase 3Biliary Tract NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05615818 · CT.gov ↗
What to watch
Phase 2Prostate CancerRecruiting
Est. primary completion 2027-06-01 · NCT04812366 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Sarcoma,Soft Tissue, Sarcoma UterusActive not recruiting
Est. primary completion 2027-08 · NCT05515575 · CT.gov ↗
What to watch
September 2027 (2)
Phase 1/2Breast CancerNot yet recruiting
Est. primary completion 2027-09 · NCT05519670 · CT.gov ↗
What to watch
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1/2Metastatic Breast Cancer, HER2 Positive Breast CarcinomaActive not recruiting
Est. primary completion 2027-11-01 · NCT03368729 · CT.gov ↗
What to watch
December 2027 (4)
Phase 3GlioblastomaActive not recruiting
Est. primary completion 2027-12 · NCT06388733 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05601440 · CT.gov ↗
What to watch
Phase 2Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma …Active not recruiting
Est. primary completion 2027-12-31 · NCT04592237 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-12-31 · NCT05990192 · CT.gov ↗
What to watch
2028 (8)
January 2028 (1)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2028-01 · NCT06180356 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2Pancreatic Adenocarcinoma MetastaticRecruiting
Est. primary completion 2028-06 · NCT06747845 · CT.gov ↗
What to watch
Phase 2Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8 …Recruiting
Est. primary completion 2028-06-07 · NCT04947254 · CT.gov ↗
What to watch
July 2028 (1)
Phase 3CancerActive not recruiting
Est. primary completion 2028-07-05 · NCT03768063 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, PALB2 Gene MutationActive not recruiting
Est. primary completion 2028-08-31 · NCT05694715 · CT.gov ↗
What to watch
December 2028 (3)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2028-12 · NCT05009082 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2028-12-25 · NCT06682780 · CT.gov ↗
What to watch
Phase 2Prostate Cancer, Oligometastatic DiseaseActive not recruiting
Est. primary completion 2028-12-31 · NCT06212583 · CT.gov ↗
What to watch
2029 (5)
April 2029 (1)
Phase 2Cancer, Tumors, Neoplasms, NeoplasiaRecruiting
Est. primary completion 2029-04-30 · NCT04341181 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2029-06-30 · NCT06953323 · CT.gov ↗
What to watch
July 2029 (1)
Phase 4Ovarian CancerRecruiting
Est. primary completion 2029-07-28 · NCT06412120 · CT.gov ↗
What to watch
August 2029 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2029-08-01 · NCT05659381 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2Brain MetastasesRecruiting
Est. primary completion 2029-12-31 · NCT05700721 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 2Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer …Recruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
2032 (2)
October 2032 (2)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2032-10-01 · NCT05460000 · CT.gov ↗
What to watch
Phase 3Ovarian CancerRecruiting
Est. primary completion 2032-10-31 · NCT06915025 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 March 2026ApprovalEC approves AKEEGA indication extension for BRCA1/2-mutated mHSPC
EU, EC · Source ↗